Drug intelligence / Profile preview

durvalumab-680LT

Development stage: Phase 2
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Durvalumab-680LT is a fluorescently labeled version of the anti-PD-L1 drug durvalumab. It is used in clinical research settings for quantitative fluorescence endoscopy (qFME) to directly measure PD-L1 levels in vivo. This modified version allows for visualization and measurement of PD-L1 expression in cancer tissues, particularly in studies investigating the heterogeneity of PD-L1 expression in cancers such as esophageal cancer and colorectal cancer. The fluorescent labeling enables researchers to track drug distribution, target expression, and changes over time in cancer tissues.

Targets

CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on durvalumab-680LT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on durvalumab-680LT.

Explore the full profile